NCT03551873View on ClinicalTrials.gov

A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®

CompletedOBSERVATIONAL
Enrollment

7

Participants

Timeline

Start Date

June 21, 2018

Primary Completion Date

December 14, 2018

Study Completion Date

December 14, 2018

Conditions
Chronic Idiopathic Constipation
Interventions
DRUG

Plecanatide

Subjects will have been breastfeeding or pumping for at least 4 weeks and must have been prescribed and taking TRULANCE® for at least 14 continuous days prior to Baseline. Breast milk for measurement of TRULANCE® (plecanatide) concentrations will be collected at Day 1.

Trial Locations (3)

27612

Synergy Research Center 001, Raleigh

33319

Syergy Research Center 003, Tamarac

91606

Synergy Research Center 002, North Hollywood

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT03551873 - A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE® | Biotech Hunter | Biotech Hunter